A detailed history of Cubist Systematic Strategies, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 70,293 shares of RCUS stock, worth $1.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
70,293
Previous 84,463 16.78%
Holding current value
$1.11 Million
Previous $1.29 Million 16.49%
% of portfolio
0.01%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$13.69 - $18.01 $193,987 - $255,201
-14,170 Reduced 16.78%
70,293 $1.07 Million
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $1.23 Million - $1.56 Million
84,463 New
84,463 $1.29 Million
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $1.41 Million - $1.88 Million
79,842 Added 42244.44%
80,031 $1.44 Million
Q2 2023

Aug 14, 2023

SELL
$16.97 - $22.03 $1.15 Million - $1.49 Million
-67,841 Reduced 99.72%
189 $3,000
Q1 2023

May 15, 2023

SELL
$15.96 - $23.15 $652,349 - $946,233
-40,874 Reduced 37.53%
68,030 $1.24 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $717,671 - $1.3 Million
36,430 Added 50.27%
108,904 $2.25 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $1.02 Million - $1.31 Million
-43,708 Reduced 37.62%
72,474 $1.9 Million
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $1.16 Million - $2.54 Million
67,294 Added 137.65%
116,182 $2.94 Million
Q1 2022

May 16, 2022

SELL
$28.92 - $41.83 $505,058 - $730,519
-17,464 Reduced 26.32%
48,888 $1.54 Million
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $1.58 Million - $2.44 Million
50,261 Added 312.35%
66,352 $2.69 Million
Q3 2021

Nov 15, 2021

SELL
$26.93 - $37.68 $357,253 - $499,862
-13,266 Reduced 45.19%
16,091 $561,000
Q2 2021

Aug 16, 2021

BUY
$22.75 - $35.77 $266,903 - $419,653
11,732 Added 66.56%
29,357 $806,000
Q1 2021

May 17, 2021

SELL
$26.16 - $41.39 $120,990 - $191,428
-4,625 Reduced 20.79%
17,625 $495,000
Q4 2020

Feb 16, 2021

SELL
$17.0 - $32.36 $242,165 - $460,968
-14,245 Reduced 39.03%
22,250 $578,000
Q3 2020

Nov 16, 2020

SELL
$17.14 - $25.47 $555,010 - $824,744
-32,381 Reduced 47.01%
36,495 $626,000
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $962,197 - $2.52 Million
68,876 New
68,876 $1.7 Million
Q3 2019

Nov 14, 2019

SELL
$6.44 - $10.18 $131,981 - $208,628
-20,494 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$7.29 - $13.38 $149,401 - $274,209
20,494 New
20,494 $163,000
Q3 2018

Nov 14, 2018

SELL
$10.88 - $14.95 $108,897 - $149,634
-10,009 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$12.24 - $17.05 $13,623 - $18,976
1,113 Added 12.51%
10,009 $123,000
Q1 2018

May 15, 2018

BUY
$15.44 - $17.71 $137,354 - $157,548
8,896 New
8,896 $137,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.